anv419
Adult Disease
Anaveon AGPhase 1/2Active
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Adult Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ipilimumab Anaveon AG | Phase 1 | CC |
tt125-802 TOLREMO therapeutics AG | Phase 1 | CC |
DARATUMUMAB Anaveon AG | Phase 1 | CC |
DEXAMETHASONE Anaveon AG | Phase 1 | CC |
FILGRASTIM Anaveon AG | Phase 1 | CC |
cc-5013 Anaveon AG | Phase 1 | CC |
CIS-DIAMMINEDICHLOROPLATINUM II Anaveon AG | Phase 1 | CC |
Same molecule, other indications
anv419 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →